Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER2-positive breast cancer

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

Roche: Scotland must improve cancer drug access

Pharma company's call comes as SMC decides not to recommend Avastin in ovarian cancer

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

Roche - Basel

Roche’s T-DM1 activity in breast cancer “outstanding”

Improves survival by six months compared to GSK’s Tykerb/Tyverb

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

Roche plans translational research centre in New York

Follows plan to close New Jersey headquarters

- PMLiVE

Roche loses Indian Tarceva patent battle with Cipla

As Novartis' Glivec patent law challenge begins again

- PMLiVE

Bayer’s Martin Hesse moves to Daiichi Sankyo Europe

Will succeed Max Schöner, who retires in December after 12-years as CFO

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

Roche - Basel

Roche says pipeline will balance cancer drug patent losses

Has 11 new molecular entities in late-stage portfolio and 11 line extensions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links